$48.00
Manufacturer: Ukraine
Ariprazol is indicated for the treatment of schizophrenia in adults.
Ariprazole is also indicated for the treatment of moderate to severe manic episodes in bipolar I disorder, as well as for the prevention of new manic episodes in adults with a previous manic episode who have responded to treatment with aripiprazole.
Description
Ingredients
active ingredient: aripiprazole;
1 tablet contains aripiprazole 15 mg (based on 100% dry matter aripiprazole);
excipients: hypromellose; croscarmellose sodium; lactose monohydrate, cellulose microcrystalline acid citric monohydrate, silicon dioxide colloidal magnesium stearate.
Dosage form
Pills.
Basic physical and chemical properties: tablets of 15 mg: tablets of white or almost white color, round shape, with a flat surface.
Pharmacotherapeutic group
Psycholeptic means. Antipsychotics. Other neuroleptics.
ATX code N05A X12.
Pharmacodynamics
Mechanism of action.
The therapeutic effect of aripiprazole in the treatment of schizophrenia and bipolar disorder type I is due to a combination of partial agonism for dopamine D2 and serotonin 5-HT1a receptors, as well as antagonism for serotonin 5-HT2a receptors. Aripiprazole is known to exhibit antagonistic properties in animal models of dopaminergic hyperactivity and agonistic properties in animal models of dopaminergic hypoactivity. Aripiprazole has high in vitro binding affinity for dopamine D2 and D3 receptors, serotonin 5-HT1a and 5-HT2a receptors, and moderate affinity for dopamine D4, serotonin 5-HT2c and 5-HT7 receptors, alpha-1 adrenoreceptors, and histamine receptors. H1. Aripiprazole also has a moderate affinity for serotonin receptors and no appreciable affinity for muscarinic receptors. Interactions with receptors other than the dopamine and serotonin subtypes may explain some of the other clinical effects of aripiprazole.
Indications
Ariprazol (aripіprazole) is indicated for the treatment of schizophrenia in adults.
Ariprazol (aripіprazole) is also indicated for the treatment of moderate to severe manic episodes in bipolar I disorder, as well as for the prevention of new manic episodes in adults with a previous manic episode who have responded to treatment with aripiprazole.
Contraindications
Hypersensitivity to aripiprazole or to any other component of the drug.
Dosage and administration
Adults.
Schizophrenia: The recommended starting dose of ariprazole is 10 or 15 mg/day and the maintenance dose is 15 mg/day. This dose is taken 1 time per day, regardless of food intake.
Ariprazol (aripіprazole) is effective in the dose range from 10 to 30 mg/day. An increase in efficacy at doses greater than a daily dose of 15 mg has not been demonstrated, although an increased dose may be beneficial to some patients.
The maximum daily dose should not exceed 30 mg.
Manic Episodes in Bipolar I Disorder: The recommended starting dose of ariprazole is 15 mg. This dose is taken 1 time per day, regardless of food intake. The drug can be prescribed as monotherapy or as part of a combination treatment. For some patients, increasing the dose may be effective. The maximum daily dose should not exceed 30 mg.
Prevention of new manic episodes in bipolar I disorder: To prevent recurrence of manic episodes in patients treated with aripiprazole as monotherapy or as part of combination treatment, the drug should be continued at the same dose. Based on the clinical condition of the patient, it is possible to correct the daily dose, including its reduction.
Patients with impaired liver function: Patients with mild or moderate hepatic impairment do not require dose adjustment. There are insufficient data to provide advice to patients with severe hepatic impairment. The dose in these patients should be titrated carefully. In patients with severe hepatic impairment, the maximum daily dose of 30 mg should be used with caution.
Patients with impaired renal function: in patients with impaired renal function, dose adjustment is not required.
Elderly patients: The efficacy of Ariprazol (aripіprazole) in the treatment of schizophrenia and bipolar I disorder in patients over the age of 65 years has not been established. Given the higher sensitivity of this patient population, consideration should be given to using lower initial doses of the drug if other clinical factors permit.
Sex: dose adjustment depending on the sex of the patient is not required.
Smoking: Due to the metabolic pathway of aripiprazole, dose adjustment is not required in smokers.
Dose Adjustment Due to Interactions: In case of co-administration of strong CYP3A4 or CYP2D6 inhibitors with aripiprazole, the dose of aripiprazole should be reduced. If a CYP3A4 or CYP2D6 inhibitor is excluded from the combination regimen, the dose of aripiprazole should be increased.
In case of simultaneous administration of strong CYP3A4 inducers with aripiprazole, the dose of aripiprazole should be increased. If a CYP3A4 inducer is excluded from the combination regimen, the dose of Ariprazol (aripіprazole) should be reduced to the recommended dose.
Recent Reviews